ଜେମଟୁଜୁମାବ ଓଜୋଗାମାଇସିନ

ଜେମଟୁଜୁମାବ ଓଜୋଗାମାଇସିନ
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	CD33
Clinical data
Trade names	Mylotarg
AHFS/Drugs.com	monograph
MedlinePlus	a618005
data	US DailyMed: Gemtuzumab_ozogamicin;
Pregnancy; category	AU: D ; US: N (Not classified yet) ; ;
Routes of; administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ; EU: Rx-only ;
Chemical and physical data
Molar mass	151500 g·mol−1
(verify)

ଇଂରାଜୀ ଲିଙ୍କ

https://or.wikipedia.org/wiki/Gemtuzumab_ozogamicin

ଜେମଟୁଜୁମାବ ଓଜୋଗାମାଇସିନ, ଏକ ବିକ୍ରୟ ନାମ ମିଲୋଟର୍ଗ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ତୀବ୍ର ମାୟେଲଏଡ ଲିଉକେମିଆର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୫] ନିର୍ଦ୍ଦିଷ୍ଟ ଭାବରେ ଏହା ସିଡି୩୩ (CD33) ଯୁକ୍ତାତ୍ମକ ରୋଗ ପାଇଁ ବ୍ୟବହୃତ ହୁଏ | ^[୫] ଏହା ଡନୋରୁବିସିନ ଏବଂ ସାଇଟାରାବିନ ସହିତ ଏକତ୍ର ବ୍ୟବହୃତ ହୁଏ ।^[୬] ଏହା ଏକ ଶିରାରେ ଧୀରେ ଧୀରେ ଇଞ୍ଜେକସନ ଆକାରରେ ଦିଆଯାଏ ।^[୫]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ସଂକ୍ରମଣ ଏବଂ ରକ୍ତସ୍ରାବ ହୋଇପାରେ ।^[୬] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯକୃତ ସମସ୍ୟା, ଲଙ୍ଗ କ୍ୟୁଟି ସିଣ୍ଡ୍ରୋମ, ବନ୍ଧ୍ୟାକରଣ ଏବଂ ଟ୍ୟୁମର ଲାଇସିସ୍ ସିଣ୍ଡ୍ରୋମ ହୋଇପାରେ ।^[୬] ^[୭] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କଲେ ଶିଶୁର କ୍ଷତି ହୋଇପାରେ ।^[୭] ଏହା ସାଇଟୋଟକ୍ସିନ ସହିତ ସଂଯୁକ୍ତ ଏକ ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବାୟୋଟିକ ।^[୬] ମୋନୋକ୍ଲୋନାଲ ଆଣ୍ଟିବଡି ସିଡି୩୩ ସହିତ ସଂଲଗ୍ନ ହୁଏ ଏବଂ ସାଇଟୋଟକ୍ସିନ ହେଉଛି କାଲିଚିଆମାଇସିନ। ^[୬]

୨୦୧୭ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଏବଂ ୨୦୧୮ରେ ୟୁରୋପରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଜେମଟୁଜୁମାବ ଓଜୋଗାମିସିନ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୭] ^[୬] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ୫ ମିଗ୍ରାର ଏକ ଭାଏଲର ମୂଲ୍ୟ ୬୩୦୦ ପାଉଣ୍ଡ ।^[୫]

ଆଧାର

↑ ^୧.୦ ^୧.୧ "Mylotarg Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 April 2020. Archived from the original on 31 October 2021. Retrieved 17 August 2020.
↑ "Gemtuzumab (Mylotarg) Use During Pregnancy". Drugs.com. 30 September 2019. Archived from the original on 29 February 2020. Retrieved 28 February 2020.
↑ "Mylotarg EPAR". European Medicines Agency (EMA). Archived from the original on 2 June 2020. Retrieved 28 February 2020.
↑ "Mylotarg 5mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 29 October 2019. Archived from the original on 18 September 2020. Retrieved 17 August 2020.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 916. ISBN 978-0857114105.
↑ ^୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ ^୬.୫ "Mylotarg". Archived from the original on 2 June 2020. Retrieved 3 December 2021.
↑ ^୭.୦ ^୭.୧ ^୭.୨ "Gemtuzumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 23 January 2021. Retrieved 3 December 2021.

[Mylotarg_APMDS-1] ୧.୦ ^୧.୧ "Mylotarg Australian prescription medicine decision summary". Therapeutic Goods Administration (TGA). 17 April 2020. Archived from the original on 31 October 2021. Retrieved 17 August 2020.

[Drugs.com_pregnancy-2] "Gemtuzumab (Mylotarg) Use During Pregnancy". Drugs.com. 30 September 2019. Archived from the original on 29 February 2020. Retrieved 28 February 2020.

[Mylotarg_EPAR-3] "Mylotarg EPAR". European Medicines Agency (EMA). Archived from the original on 2 June 2020. Retrieved 28 February 2020.

[4] "Mylotarg 5mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 29 October 2019. Archived from the original on 18 September 2020. Retrieved 17 August 2020.

[BNF81-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 916. ISBN 978-0857114105.

[EPAR2021-6] ୬.୦ ^୬.୧ ^୬.୨ ^୬.୩ ^୬.୪ ^୬.୫ "Mylotarg". Archived from the original on 2 June 2020. Retrieved 3 December 2021.

[AHFS2021-7] ୭.୦ ^୭.୧ ^୭.୨ "Gemtuzumab Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 23 January 2021. Retrieved 3 December 2021.

[୧]

[୨]

[୪]

[୩]

[୫]

[୬]

[୭]